

# SIRIC MONTPELLIER CANCER

## “8<sup>th</sup> ANNUAL MEETING”

25 JUNE 2021

In collaboration with FHU EVOCAN & Pôle Biologie Santé



8h45 Welcome

## SESSION 1

### Cancer research from bench to preclinical studies in Montpellier: highlights 2020-2021

Chairman : Philippe PASERO (IGH, Montpellier) & Serge ROCHE (CRBM, Montpellier)

- 9h00** Notching up the resensitization against EGFR TKIs in lung adenocarcinoma harboring EGFR “gatekeeper” mutations  
Antonio MARAVER (IRCM, Montpellier)
- 9h30** Targeting the ubiquitin-like molecule NEDD8 for therapeutic intervention  
Dimitri XIRODIMAS (CRBM, Montpellier)
- 10h00** Spatial chromatin organization in normal and pathological hematopoietic cells  
Eric SOLER (IGMM, Montpellier)
- 10h30** More than a crosstalk, histone marks can be drivers of the changes in splicing essential for EMT  
Reini FERNANDEZ DE LUCO (IGH, Montpellier)

**11h00 Coffee break**

Streaming video 

## SESSION 2

### Keynote lecture

Chairman : Dan FISHER (IGMM, Montpellier)

- 11h30** Cancer evolution, immune evasion and metastasis  
Charles SWANTON (The Francis Crick Institute, London)

### Keynote lecture

Chairman : David AZRIA (ICM, Montpellier)

- 12h00** Micron-Scale AI-driven Radiation Therapy driven Multi-Parametric Imaging  
Nikolaos PARAGYIOS (Thérapanacea, Paris)

**12h30 Lunch**

Streaming video 

### SESSION 3

#### Patient involvement in cancer research

Chairman : Maguy DEL RIO, Cyril SARRAUSTE de MENTHIÈRE

**13h30** Bettina RYLL (Melanoma Patient Network Europe, Uppsala)

### SESSION 4

#### Recent updates in clinical and translational research

Chairman :

**14h00** CAR-T cells: Treatment of today, treatment of the future?

Guillaume CARTRON (CHU de Montpellier)

**14h30** Untangling tumor adaptive responses to select new drug combinations

Diego TOSI (ICM, Montpellier)

**15h00** xxxxxxxx

**15h30** Coffee break

Streaming video 

### SESSION 5

#### Emerging groups of Montpellier Cancer Research

Chairman : Ula HIBNER (IGMM, Montpellier) & Claude SARDET (IRCM, Montpellier)

**16h00** Using Intervention Mapping to co-create with stakeholders an intervention to facilitate return-to-work after breast cancer

Guillaume BROU (Epsilon, Montpellier)

**16h20** BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Charles HERBAUX (CHU de Montpellier, IGH)

**16h40** Citrullination of RNA Polymerase II controls Transcription plasticity in Breast Cancer

Priyanka SHARMA (IRCM, Montpellier)

**17h00** Understanding the immune microenvironment to improve immunotherapy for brain tumors

Alexandra GARANCHER (IRCM, Montpellier)

**17h20** Closure